Ozempic

CMS launches Medicare GLP-1 Bridge program July 2026, offering Novo Nordisk's Wegovy at $50 monthly copay. Amazon Pharmacy expands oral Ozempic access.

Novo Nordisk's Q1 sales of $15.17B beat estimates, with Wegovy pill reaching 2M prescriptions. Company raised 2026 guidance to $42.39-$46.24B; shares surged 7.11%.

Novo Nordisk reports positive phase 3a trial results for oral semaglutide in children with type 2 diabetes, planning 2026 regulatory filings for potential first pediatric GLP-1 approval.

Novo Nordisk's 72% crash from peaks sparks debate: value trap or buying opportunity amid GLP-1 market competition from Eli Lilly.

Over 40 Indian pharma companies launched generic semaglutide after patent expiration, pricing treatments 70% below Novo Nordisk's originals. Market expansion planned globally.

Hims & Hers surges 40% after Novo Nordisk partnership resolves litigation, enabling authorized distribution of Wegovy and Ozempic. Stock trades under 20x forward P/E.

Novo Nordisk cuts GLP-1 drug prices 50% to $675/month starting 2027 amid clinical setbacks and competitive pressure from rivals like Eli Lilly.

Novo Nordisk stock down 67% offers entry point for long-term investors. Strong GLP-1 market position, attractive valuation metrics, and growth potential despite upcoming competition.